Litcius/Paper detail

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke, Alexa P. Kollmeier, Elizabeth C. Hsia, Ramanand A. Subramanian, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T Ritchlin

2020The Lancet322 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePsoriatic arthritisInternal medicinePlaceboClinical endpointRheumatologyArthritisApremilastPlacebo-controlled studyTNF inhibitorRandomized controlled trialSurgeryTumor necrosis factor alphaEtanerceptDouble blindPathologyAlternative medicineSpondyloarthritis Studies and TreatmentsPsoriasis: Treatment and PathogenesisRheumatoid Arthritis Research and Therapies
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial | Litcius